What is Rael?
Rael operates at the intersection of wellness and consumer packaged goods, offering a comprehensive suite of products designed to support women throughout their entire menstrual cycle. Founded by Yanghee Paik, the company distinguishes itself by integrating Korean beauty innovation with a holistic approach to personal health. Its product line is specifically formulated for individuals with varying needs, including those managing irregular cycles or specific health conditions like PCOS. By prioritizing clean, effective ingredients and sustainable practices, Rael has established a strong market position as a trusted brand for consumers seeking transparency and efficacy in their personal care routines.
How much funding has Rael raised?
Rael has raised a total of $52.9M across 3 funding rounds:
Series A
$17.5M
Debt
$350K
Series B
$35M
Series A (2018): $17.5M with participation from SoftBank Ventures Asia, Mirae Asset Venture Investment, and Pritzker Group Venture Capital
Debt (2020): $350K led by PPP
Series B (2022): $35M supported by Signite Partners, Colopl Next, Aarden Partners, and ST Capital
Key Investors in Rael
Signite Partners
A venture capital firm under the Shinsegae Group that focuses on discovering and investing in startups that innovate lifestyle through technology in the beauty, fashion, and retail sectors.
Colopl Next
A venture capital firm established in 2015 that invests in a wide range of startups across various industries, primarily targeting BtoC entertainment sectors and supporting young entrepreneurs with high growth potential.
SoftBank Ventures Asia
The early-stage venture capital arm of the SoftBank Group, specializing in ICT investments including AI, IoT, and smart robotics, with a focus on plugging startups into the global SoftBank ecosystem.
What's next for Rael?
With the recent infusion of capital, Rael is well-positioned to deepen its penetration into the global wellness market. The strategic focus will likely shift toward enhancing supply chain resilience, expanding its digital-first distribution channels, and potentially diversifying its product offerings to include more specialized health-tech solutions. As the company matures, the emphasis will remain on maintaining its commitment to clean-label standards while scaling its operational infrastructure to meet the rising demand for holistic, cycle-conscious health products. Investors are closely watching how Rael utilizes this backing to solidify its leadership in the competitive feminine care landscape.
See full Rael company page
